» Articles » PMID: 9850070

3-(Iodoacetamido)-benzoylurea: a Novel Cancericidal Tubulin Ligand That Inhibits Microtubule Polymerization, Phosphorylates Bcl-2, and Induces Apoptosis in Tumor Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 1998 Dec 16
PMID 9850070
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

3-(Iodoacetamido)-benzoylurea (3-IAABU) is a newly synthesized antitubulin compound with a molecular weight of 347. 3-IAABU exhibited anticancer activity in a variety of tumor cell lines with ID90 in the range of 0.015-0.29 microM for leukemic cells and 0.06-0.92 microM for solid tumors. Higher selectivity against malignant cells was observed with 3-IAABU than that with vinblastine and paclitaxel. It inhibits microtubule assembly in tubulin systems either with or without microtubule-associated proteins (ID50 was 0.1 microM and 1.2 microM, respectively) and microtubule depolymerization was not affected, indicating an inhibition of polymerization by binding of 3-IAABU to the heterodimeric subunit of tubulin. 3-IAABU was shown to inhibit the binding of colchicine, a subunit binding compound, but did not inhibit binding of vinblastine and guanosine 5'-triphosphate/guanosine 5'-diphosphate, indicating that colchicine site corresponds to the site that 3-IAABU locates. Tumor cells treated with 3-IAABU showed scattered chromosomes in metaphase. Normal microtubule architecture or spindle apparatus was absent in these cells; instead, punctuated aggregates of tubulin were found by an immunofluorescent staining. Cell cycle analyses showed an accumulation of tumor cells at M phase after a 4-h treatment with 3-IAABU. The phosphorylated bcl-2 representative of an inactivated form of the oncoprotein was found in the cells 12 h after treatment with 3-IAABU. These cells progressed to apoptosis within 16 h. As a new tubulin ligand, 3-IAABU could be a promising agent in cancer chemotherapy.

Citing Articles

M3, a natural lignan xyloside, exhibits potent anticancer activity in HCT116 cells.

Shen W, Zhao Y, Chen H, Zhang T, Wu S, Liu P Oncol Lett. 2019; 17(2):2117-2122.

PMID: 30675278 PMC: 6341843. DOI: 10.3892/ol.2018.9823.


Ultrapotent vinblastines in which added molecular complexity further disrupts the target tubulin dimer-dimer interface.

Carney D, Lukesh 3rd J, Brody D, Brutsch M, Boger D Proc Natl Acad Sci U S A. 2016; 113(35):9691-8.

PMID: 27512044 PMC: 5024590. DOI: 10.1073/pnas.1611405113.


Synthesis of a Potent Vinblastine: Rationally Designed Added Benign Complexity.

Allemann O, Brutsch M, Lukesh 3rd J, Brody D, Boger D J Am Chem Soc. 2016; 138(27):8376-9.

PMID: 27356080 PMC: 4945418. DOI: 10.1021/jacs.6b04330.


Identification of Simple Compounds with Microtubule-Binding Activity That Inhibit Cancer Cell Growth with High Potency.

Yang W, Shimada K, Delva D, Patel M, Ode E, Skouta R ACS Med Chem Lett. 2012; 3(1):35-38.

PMID: 22247791 PMC: 3256933. DOI: 10.1021/ml200195s.


Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1.

Pathan N, Aime-Sempe C, Kitada S, Basu A, Haldar S, Reed J Neoplasia. 2002; 3(6):550-9.

PMID: 11774038 PMC: 1506558. DOI: 10.1038/sj.neo.7900213.